David Schoenfeld, MD, PhD, Yale School of Medicine, New Haven, CT, reveals his future plans in the investigation of decoy-resistant IL-18 (DR-18) plus anti-CTLA-4 blockade for both renal cell carcinoma and melanoma. Whilst preclinical work is still ongoing to determine the exact mechanisms of this combination therapy, there is strong evidence to begin early phase trials which are currently being organised. This interview took place at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть